Forecast

The analysts' average price target is €44.76 (+33.29%). The median is €43.04 (+28.17%).

Buy	9
Hold	0
Sell	0

News Go to news feed

Septerna reaches all-time high of $50

Septerna’s stock reached an all-time high of $50 and is currently trading at $49.47, with a market capitalization of about $2.28 billion. The stock rose 326% over the past year and 71% year-to-date; InvestingPro rates the current level as fair. Analysts updated price targets following progress with SEP-479: H.C. Wainwright raised its target to $60 and reiterated a buy rating, Stifel set a $49 target, while Guggenheim later cut its target to $45 after negative industry signals. » More on de.investing.com
Septerna hits record high at $38.21

Septerna’s shares rose to a record high of $38.21 and are trading just below the 52-week high; market capitalization is $1.71 billion and the stock has gained 221.8% over the past year. Analysts remain largely optimistic and have reaffirmed or raised price targets (including $40, $45, $43, $53) despite an InvestingPro analysis that classifies the stock as overvalued based on fair‑value metrics. Positive Phase 1 results for the oral drug SEP-631 and momentum behind other programs support the growth outlook. » More on de.investing.com

Financials

In the last quarter, Septerna had revenue of €23.44M and net profit of -€11.42M

(EUR)	Jun 2026	YoY
Revenue	23.44M	23,111.81%
Gross profit	23.44M	23,111.81%
Net profit	-11.42M	45.81%
EBITDA	-10.57M	49.02%

Fundamentals

Metric	Value
Market capitalization	€1.51B
Number of shares	45.08M
52-week high/low	€43.99 - €10.31
Dividends	No
Beta	2.28
P/E ratio	-72.06
PEG ratio	-0.40
P/B ratio	4.53
P/S ratio	17.74

Company profile

Septerna, Inc., ein Biotechnologieunternehmen in der klinischen Phase, entdeckt und entwickelt orale niedermolekulare G-Protein-gekoppelte Rezeptoren (GPCR) zur Behandlung von Endokrinologie, Immunologie und Entzündungen sowie Stoffwechselkrankheiten. Das Unternehmen entwickelt SEP-786, einen oralen niedermolekularen PTH1R-Agonisten für Hypoparathyreoidismus; SEP-631, einen oralen niedermolekularen MRGPRX2-NAM für chronische spontane Urtikaria und andere Mastzellenerkrankungen; TSHR Program, einen oralen niedermolekularen TSHR-NAM für Morbus Basedow und Schilddrüsenerkrankungen. Darüber hinaus entwickelt das Unternehmen orale niedermolekulare Einzel- und Multi-Inkretin-Rezeptor-Agonisten für Stoffwechselstörungen wie Fettleibigkeit und Typ-2-Diabetes. Septerna, Inc. war früher als GPCR NewCo, Inc. bekannt und änderte im Juni 2021 seinen Namen in Septerna Inc. Das Unternehmen wurde im Jahr 2019 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien.